ChemoCentryx, Inc. (CCXI) Reaches $8.38 After 3.00% Down Move; Boston Common Asset Management Boosted Ing Groep N V Sponsored Adr (ING) Position By $336,294

January 14, 2018 - By Hazel Jackson

The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) is a huge mover today! The stock decreased 6.89% or $0.62 during the last trading session, reaching $8.38. About 102,044 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 60.64% since January 14, 2017 and is uptrending. It has outperformed by 43.94% the S&P500.The move comes after 8 months negative chart setup for the $408.67M company. It was reported on Jan, 14 by Barchart.com. We have $8.13 PT which if reached, will make NASDAQ:CCXI worth $12.26 million less.

Boston Common Asset Management Llc increased Ing Groep N V Sponsored Adr (ING) stake by 19.1% reported in 2017Q3 SEC filing. Boston Common Asset Management Llc acquired 18,683 shares as Ing Groep N V Sponsored Adr (ING)’s stock rose 17.61%. The Boston Common Asset Management Llc holds 116,488 shares with $2.15 million value, up from 97,805 last quarter. Ing Groep N V Sponsored Adr now has $77.50 billion valuation. The stock increased 1.30% or $0.26 during the last trading session, reaching $20.31. About 2.33 million shares traded. ING Groep N.V. (NYSE:ING) has risen 45.69% since January 14, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Among 3 analysts covering ChemoCentryx (NASDAQ:CCXI), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. ChemoCentryx had 5 analyst reports since September 3, 2015 according to SRatingsIntel. The firm has “Mkt Outperform” rating given on Tuesday, February 21 by JMP Securities. On Thursday, August 10 the stock rating was maintained by JMP Securities with “Buy”. The firm has “Hold” rating given on Tuesday, August 8 by Cowen & Co. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) has “Sell” rating given on Monday, September 21 by Zacks. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) has “Sell” rating given on Thursday, September 3 by Zacks.

Investors sentiment decreased to 1.14 in 2017 Q3. Its down 0.26, from 1.4 in 2017Q2. It is negative, as 12 investors sold ChemoCentryx, Inc. shares while 23 reduced holdings. 12 funds opened positions while 28 raised stakes. 23.75 million shares or 2.21% less from 24.29 million shares in 2017Q2 were reported. Goldman Sachs Gp Inc holds 220,440 shares. Moreover, Blackrock has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). 2.22M are held by Wasatch Advisors Inc. Baker Bros Advsr Limited Partnership holds 49,064 shares. Connor Clark & Lunn Investment Mngmt Ltd reported 65,775 shares. Rhumbline Advisers owns 29,953 shares. Renaissance Tech Ltd Liability Com accumulated 926,881 shares. Smith Asset Mgmt Grp Ltd Partnership holds 0.01% or 27,370 shares. Legal General Grp Public Limited Co reported 5,113 shares. Ameritas has invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Paw invested 1.24% in ChemoCentryx, Inc. (NASDAQ:CCXI). Arrowstreet Capital Partnership reported 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Illinois-based Citadel Lc has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). California Employees Retirement Systems reported 62,800 shares stake. Wells Fargo Com Mn reported 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI).

Since August 1, 2017, it had 0 insider purchases, and 1 insider sale for $22,667 activity. 2,250 ChemoCentryx, Inc. (NASDAQ:CCXI) shares with value of $22,667 were sold by LUCAS ROGER C.

Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on March, 13. They expect $-0.22 EPS, down 37.50% or $0.06 from last year’s $-0.16 per share. After $-0.13 actual EPS reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts 69.23% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: